W W Grainger Inc vs Revolution Medicines Inc. Common Stock — how do they compare? W W Grainger Inc trades at $1,289.35 (market cap $59.76B), while Revolution Medicines Inc. Common Stock trades at $189.32 (market cap $40.32B). The key difference: W W Grainger Inc is the larger of the two by market cap, and W W Grainger Inc pays a 0.79% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| GWW | RVMD | |
|---|---|---|
Market Cap | $59.76B | $40.32B |
Volume | 186,697 | 4,855,734 |
Sector | Industrials | Health |
52-Week High | $1.40K | $221.15 |
52-Week Low | $918.18 | $47.50 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $61.96B | $37.02B |
Dividend Yield | 0.79% | — |
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,289.79, up 2.08% today, with a bearish technical signal but strong fundamentals including a 47.92% ROE and recent earnings beats. The company reported Q2 2026 EPS of $12.01, beating expectations, and maintains a net income margin of 9.92%. Recent developments include the acquisition of technology assets from Adroit Worldwide Media for $210 million and the opening of a new distribution center in Oregon, supporting growth initiatives.
The outlook is mixed: analyst consensus is a hold with a $1,310 price target, but strong profitability and strategic acquisitions offer upside. Risks include high valuation multiples like a P/E of 32.34 and competitive pressures in industrial distribution. Cash flow trends improved in 2026, with net cash flow near breakeven, reducing liquidity concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →